Rather than targeting GLP-1 receptors alone, it's a dual agonist activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously
Regular healthcare consultations, careful monitoring, and adherence to professional guidance help patients maximize benefits while minimizing risks
Download our white paper here: Related solutions Discover new approaches to cardiovascular clinical trials to bring game-changing therapies to patients faster
Pegah, A., Abbasi-Oshaghi, E., Khodadadi, I., Mirzaei, F., & Tayebinia, H
You might already know that semaglutide the active ingredient in Wegovy injection pens can help people living with obesity lose weight